Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28432454 | 0.94 | TPMT (0.40) | TPMTPDPK1GSK3BCA1CA2 | |
| SCHEMBL29009777 | 0.81 | SRC (0.38) | SRCKEAP1NFE2L2CYP2D6 | |
| SCHEMBL1142809 | 0.79 | SRC (0.55) | CA1CA2SRCCYP2D6 | |
| SCHEMBL9157493 | 0.79 | HDAC3 (0.47) | CA1CA2 | |
| SCHEMBL241909 | 0.78 | SRC (0.56) | SRCKEAP1NFE2L2CYP2D6 | |
| SCHEMBL28232476 | 0.78 | SRC (0.56) | SRCKEAP1NFE2L2CYP2D6 | |
| SCHEMBL28232530 | 0.78 | SRC (0.56) | SRCKEAP1NFE2L2CYP2D6 | |
| SCHEMBL11254414 | 0.77 | POLB (0.41) | SRCCNR1KEAP1NFE2L2 | |
| SCHEMBL2399005 | 0.77 | KEAP1 (0.53) | CNR1KEAP1NFE2L2 | |
| SCHEMBL11405448 | 0.77 | CYP2C9 (0.46) | CNR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098517-B1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | MSD KK (JP) | 2013-12-18 | — | — | EP | disclosed |
| US-8367708-B2 | Phenyl-isoxazol-3-ol derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2098517-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | GPR119, FFAR3, FFAR2 | TPMT 4670/4885PDPK1 2244/4885GSK3B 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.